Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents
Journal of Paediatrics and Child Health · 2025-01 · 61 (1) · 7-11
DOI: 10.1111/jpc.16734 ↗At a glance
Journal article in Journal of Paediatrics and Child Health, published online on 2024-12-06. Written by Daniel Wright and 3 co-authors. Institution: Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria, Australia. Major MEDLINE topics: Transgender Persons. Cited 16 times so far (Crossref); 48 references. Funded by: The Royal Children's Hospital Foundation, The Hugh D.T. Williamson Foundation, NHMRC.
Abstract (original language)
The use of puberty blockers and gender‐affirming hormones by transgender adolescents is the subject of an ongoing public debate. In this paper, we address one central ethical aspect of the debate – the question of what sort of benefits these treatments provide and how to evaluate the significance of these benefits in relation to risks. We argue that the intended benefit of these treatments is best understood as appearance congruence, namely, to create or maintain alignment of physical appearance with one's gender identity. The common focus on the mental health benefits associated with these treatments may obscure a range of experiential benefits sought by young people, such as positive gender experiences and being treated by others as one's identified gender. We also address concern about the risk that young people may revert to their assigned gender (de‐transition) and experience regret. We distinguish between de‐transition and regret, highlighting that regret appears to occur in a minority of instances of de‐transition or discontinuation of hormone treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria, Australia.
- Centre for Social Ethics and Policy (CSEP), Law School, School of Social Sciences, The University of Manchester, Manchester, UK.
- Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Adolescent Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.
ORCID profiles: Daniel Wright
Funding
- The Royal Children's Hospital Foundation
- The Hugh D.T. Williamson Foundation
- NHMRC
- Royal Children's Hospital Foundation
- National Health and Medical Research Council
Cite
APA
Wright, D., Pang, K. C., Giordano, S., & Gillam, L. (2025). Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents. Journal of Paediatrics and Child Health, 61(1), 7-11. https://doi.org/10.1111/jpc.16734
Vancouver
Wright D, Pang KC, Giordano S, Gillam L. Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents. Journal of Paediatrics and Child Health. 2025;61(1):7-11. doi:10.1111/jpc.16734
BibTeX
@article{Wright2025,
author = {Wright, Daniel and Pang, Ken C and Giordano, Simona and Gillam, Lynn},
title = {Evaluating the benefits and risks of puberty blockers and gender‐affirming hormones for transgender adolescents},
journal = {Journal of Paediatrics and Child Health},
year = {2025},
volume = {61},
number = {1},
pages = {7--11},
doi = {10.1111/jpc.16734}
}
EUVIMED